| Document |
Document Title |
|
WO/2024/043632A1 |
The present invention relates to a polysorbate-succinic acid-carnitine complex, and a bioactive substance or a drug delivery composition comprising same. More specifically, provided is an oral insulin preparation enabling insulin to be o...
|
|
WO/2024/044721A1 |
Embodiments of the present disclosure provide compositions and methods for injectable recombinant protein-based hydrogels for therapeutic delivery. Embodiments of the composition and methods comprise a recombinant protein, a cell consort...
|
|
WO/2024/041415A1 |
A collagenase liposome inhalant, used for treating pulmonary fibrosis after pulmonary inhalation. Use of a collagenase liposome in the preparation of an inhalant for treating pulmonary fibrosis, and a preparation method for the collagena...
|
|
WO/2024/040769A1 |
The present application provides a sericin protein peptide having a moisturizing function, a method for preparing same, and use thereof. According to a first aspect of the present application, a sericin protein peptide having a moisturiz...
|
|
WO/2024/041535A1 |
The present disclosure relates to a nano-composition, a preparation method therefor, and use thereof. The nano-composition is formed by self-assembly of an oligopeptide containing a tryptophan dipeptide motif and cisplatin. The general f...
|
|
WO/2024/043506A1 |
The present invention relates to a hydrogel-based wound dressing containing a protein extract. The wound dressing: comprises a polyethylene glycol, white Vaseline, 1,2-hexanediol, ethylhexylglycerin, a sodium hyaluronate, a protein extra...
|
|
WO/2024/042313A1 |
The invention provides cyclic peptides that are able to disrupt the typical response to hypoxia and which have particular utility in the treatment of cancers and von Hippel- Lindau disease.
|
|
WO/2024/042165A2 |
The present invention provides novel RNA-guided nuclease proteins and nucleic acid targeting system comprising such for cleaving and/or modifying the target nucleotide of interest.
|
|
WO/2024/040593A1 |
The present invention provides an anti-pneumonia drug, a preparation method therefor, and use thereof. The anti-pneumonia drug of the present invention comprises a carrier loaded with an inhibitor. The inhibitor is an inhibitor capable o...
|
|
WO/2024/043715A1 |
The present invention relates to a composition and uses thereof, the composition comprising, as active ingredients, induced pluripotent stem cell-derived exosomes, and collagen or hyaluronic acid or salts thereof. The composition accordi...
|
|
WO/2024/044569A1 |
The present disclosure relates to compositions comprising capsicum, functional mineral compounds, and yeast cell wall. Furthermore, methods of feeding the composition to animals such as bovines are provided to demonstrate beneficial effe...
|
|
WO/2024/044773A1 |
The present invention relates generally to methods and compositions useful for treating skin on a subject. In some embodiments, methods and compositions disclosed herein comprise topical or oral administration of nutraceutical and/or top...
|
|
WO/2024/042226A2 |
A method for producing a purified morphinan-glycoside conjugate. The method includes the steps of contacting a morphinan compound with an activated saccharide or activated oligosaccharide and a glycosyltransferase in a reaction mixture u...
|
|
WO/2024/044751A2 |
Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the same and methods of use for treating cancer and inhibiting PRX3 are also provi...
|
|
WO/2024/044647A1 |
Provided herein are polypeptides, compositions, and methods for treating a cancer in an individual using a polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain. Also provided herein are nucleic acids encoding such poly...
|
|
WO/2024/042148A1 |
The present invention relates to compositions, solutions, and patches as well as methods for using the same in treatment, prevention, or amelioration of haemorrhage in a subject. In particular, the present invention relates to methods fo...
|
|
WO/2024/041532A1 |
The present disclosure relates to a complex comprising a tetravalent platinum moiety and an oligopeptide as an axial ligand chemically linked to the platinum.
|
|
WO/2024/043643A1 |
The present invention relates to an IL2 variant and a protein complex comprising same, a production method therefor, and a use thereof, the protein complex selectively increasing effector T cell activity, thereby being capable of reducin...
|
|
WO/2024/044744A2 |
Provided according to some embodiments is a compound of Formula (I), or a pharmaceutically acceptable salt or prodrug thereof. Pharmaceutical compositions comprising the same and methods of use for treating cancer and inhibiting PRX3 are...
|
|
WO/2024/044759A2 |
The present disclosure relates to method of making tiny RNAs loaded on Argonaute protein using exonucleases.
|
|
WO/2024/044716A2 |
Provided are recombinant cytokine receptors that comprise an IL-2 receptor polypeptide that is tethered to IL-2 cytokine. Also provided herein are Treg cells comprising recombinant cytokine receptors and methods of use.
|
|
WO/2024/041604A1 |
The present invention belongs to the fields of biotechnology and biopharmaceutical technology. Disclosed is use of a yogurt-derived polypeptide in the preparation of a drug for delaying telomere shortening and an anti-aging drug. The pre...
|
|
WO/2024/041372A1 |
Provided are a branched polypeptide vector and a variant thereof. The branched polypeptide has a sequence set forth in the following: Xaa1(P2)-Xaa1-Xaa1(P1)-Xaa1-Xaa1(P2), or Xaa1(P1)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P2)-Xaa1-Xaa1(P1), or Xaa1(P2...
|
|
WO/2024/044304A1 |
A CRISPR-Cas9 system for treating a disease, disorder, or condition associated with one or more somatic mutations in a subject in need of treatment thereof is disclosed. The system comprises a sgRNA-guided Cas9, wherein the sgRNA targets...
|
|
WO/2024/044745A2 |
The present disclosure provides pharmaceutical compositions that comprise a microparticle or nanoparticle suspension of a collagen IV-derived peptide or pharmaceutically-acceptable salt thereof, as well as uses of these suspensions for t...
|
|
WO/2024/042518A1 |
Provided herein a method of reducing, alleviating or treating the side effects of GLP-1 receptor agonist therapy (such as gastrointestinal side effects), comprising administering a composition comprising an effective amount of GLP-1 rece...
|
|
WO/2024/044098A2 |
This disclosure provides compounds, compositions, and methods to treat medical disorders, such as complement-mediated disorders, including complement C1s-mediated disorders.
|
|
WO/2024/044670A1 |
The present disclosure relates to the field of cell therapy, and more specifically, to improving CAR and/or TCR function through cytokine signaling or cytokine receptor signaling.
|
|
WO/2024/038888A1 |
The present invention addresses the problem of providing technology for heightening a small intestinal absorption property of a peptide having physiological functionality. This problem is solved via a composition containing a peptide com...
|
|
WO/2024/038462A1 |
rovided are compositions-of-matter comprising non-pathogenic bacteria capable of homing to a tumor, said bacteria comprising a heterologous polynucleotide comprising a nucleic acid sequence encoding a Pro Domain (TPD) polypeptide of TNFÎ...
|
|
WO/2024/040151A1 |
Dosing regimens and methods for administering combination therapies combining SIRPαFc fusion proteins and anti-CD38 antibodies are provided, such as the SIRPαFc fusion protein TTI-622 and the anti-CD38 antibody isatuximab. The dosing r...
|
|
WO/2024/038361A1 |
The subject of the invention is an oral, lecithin-comprising composition for breastfeeding mothers, characterized in that it further comprises bromelain and that lecithin is deoiled. The object of the invention is also the use of the com...
|
|
WO/2024/037572A1 |
An isolated interleukin-2 (IL-2) variant that exhibits reduced affinity to the α-subunit of IL-2 receptor (IL-2R), for use as immunotherapeutic agents. In addition, a pharmaceutical composition comprising the isolated IL-2 variant, and ...
|
|
WO/2024/036387A1 |
The present invention relates to a concentrate of proteins and peptides derived from mesenchymal stem cells that can be used by the pharmaceutical, veterinary, cosmetic or food industries. The protein and peptide concentrate derived from...
|
|
WO/2024/038934A1 |
The present invention relates to a composition containing osmotin protein as an active ingredient for the prevention, alleviation, or treatment of Parkinson's disease. The osmotin protein has the effects of: alleviating behavioral and mo...
|
|
WO/2024/036373A1 |
Described herein are methods and related compositions for determining the likelihood of neurological post-acute sequelae of COVID-19 (NP ASC) in a subject based on the levels of biomarkers in a combination of biomarkers from a biological...
|
|
WO/2023/031380A9 |
The invention relates to a dosage regime for compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors for use in the treatment of obesity and related conditions.
|
|
WO/2024/038165A1 |
The present disclosure provides T cell receptor (TCR) fusion proteins comprising a TCR that binds to a GVYDGREHTV (SEQ ID NO:34) HLA-A*02 complex that is covalently linked to a T cell engaging domain that binds a protein expressed on a c...
|
|
WO/2024/040156A2 |
A novel compound and method of treating and preventing coronavirus infection in a patient is presented. Cyclic γ AApeptide pan-coronavirus inhibitors which bind to RBD and HR1 on the spike protein were found to exhibit high proteolytic ...
|
|
WO/2024/038106A1 |
The present invention relates to an inhibitor protein of ligands of epidermal growth factor receptor (EGFR), an antibody or fragment thereof that specifically recognizes said inhibitor protein, a polynucleotide comprising a nucleotide se...
|
|
WO/2024/038051A1 |
A WNT5A peptide for use in the reduction or elimination of tumour growth or invasive behaviour of a tumour in a patient diagnosed with a cancer and having said tumour. The present invention further relates to a WNT5A peptide for use in n...
|
|
WO/2024/040017A2 |
Compositions are provided which feature mixtures of at least a first and second peptoid. The second peptoid has a terminal aliphatic moiety, while the first peptoid lacks a terminal aliphatic moiety. These compositions have various end u...
|
|
WO/2024/038157A1 |
The present invention relates to a pharmaceutical composition for use in the treatment or prophylaxis of a coronavirus infectious disease, particularly to a composition comprising of at least two and most particularly up to 12 different ...
|
|
WO/2024/040258A2 |
The present disclosure provides engineered beta-galactosidase polypeptides, recombinant polynucleotides encoding the engineered beta-galactosidases, and methods of using the engineered beta-galactosidases and recombinant polynucleotides ...
|
|
WO/2024/037322A1 |
Disclosed in the present invention are an IL-15 mutant-Fc/IL-15Rα subunit-Fc heterodimer and the use thereof. The heterodimeric protein comprises protein a and protein b, wherein the protein a comprises an IL-15 mutant and a first Fc mu...
|
|
WO/2024/040247A1 |
The present disclosure provides protease-activated IFN proproteins. The IFN proproteins comprises an IFN moiety that is sterically hindered from binding to its receptor through attachment to an Fc moiety via a protease-cleavable linker. ...
|
|
WO/2023/014970A9 |
Disclosed herein are NorA peptide inhibitors, protein scaffolds including the NorA peptide inhibitor, and antibody-based molecules that bind NorA, as well as compositions containing the same. Also disclosed are combinations therapeutic a...
|
|
WO/2024/038168A1 |
The present invention provides novel RNA-guided nuclease proteins and nucleic acid targeting system comprising such for cleaving and/or modifying the target nucleotide of interest.
|
|
WO/2024/040014A2 |
A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with spe...
|
|
WO/2024/037520A1 |
Disclosed in the present invention are a new compound as represented by general formula I, a pharmaceutically acceptable salt, an enantiomer, a diastereoisomer and a racemate thereof, and a pharmaceutical composition containing the compo...
|
